Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2.
Shinjo SK, de Souza FHC, Borges IBP, Dos Santos AM, Miossi R, Misse RG, Medeiros-Ribeiro AC, Saad CGS, Yuki EFN, Pasoto SG, Kupa LVK, Ceneviva C, Seraphim JC, Pedrosa TN, Vendramini MBG, Silva CA, Aikawa NE, Bonfá E. Shinjo SK, et al. Among authors: yuki efn. Rheumatology (Oxford). 2022 Aug 3;61(8):3351-3361. doi: 10.1093/rheumatology/keab773. Rheumatology (Oxford). 2022. PMID: 34664616 Free PMC article. Clinical Trial.
Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus.
Yuki EFN, Borba EF, Pasoto SG, Seguro LP, Lopes M, Saad CGS, Medeiros-Ribeiro AC, Silva CA, de Andrade DCO, Kupa LVK, Betancourt L, Bertoglio I, Valim J, Hoff C, Formiga FFC, Pedrosa T, Kallas EG, Aikawa NE, Bonfa E. Yuki EFN, et al. Arthritis Care Res (Hoboken). 2022 Apr;74(4):562-571. doi: 10.1002/acr.24824. Epub 2022 Mar 4. Arthritis Care Res (Hoboken). 2022. PMID: 34806342 Free PMC article. Clinical Trial.
Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study.
Aikawa NE, Kupa LVK, Pasoto SG, Medeiros-Ribeiro AC, Yuki EFN, Saad CGS, Pedrosa T, Fuller R, Shinjo SK, Sampaio-Barros PD, Andrade DCO, Pereira RMR, Seguro LPC, Valim JML, Waridel F, Sartori AMC, Duarte AJS, Antonangelo L, Sabino EC, Menezes PR, Kallas EG, Silva CA, Bonfa E. Aikawa NE, et al. Among authors: yuki efn. Lancet Rheumatol. 2022 Feb;4(2):e113-e124. doi: 10.1016/S2665-9913(21)00327-1. Epub 2021 Dec 3. Lancet Rheumatol. 2022. PMID: 34901885 Free PMC article.
Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients.
Silva CA, Medeiros-Ribeiro AC, Kupa LVK, Yuki EFN, Pasoto SG, Saad CGS, Fusco SRG, Pereira RMR, Shinjo SK, Halpern ASR, Borba EF, Souza FHC, Guedes LKN, Miossi R, Bonfiglioli KR, Domiciano DS, Shimabuco AY, Andrade DCO, Seguro LPC, Fuller R, Sampaio-Barros PD, Assad APL, Moraes JCB, Goldenstein-Schainberg C, Giardini HAM, Silva HC, Martins VAO, Villamarin LEB, Novellino RS, Sales LP, Araújo CSR, Silva MSR, Filho DMN, Lopes MH, Duarte AJS, Kallas EG, Aikawa NE, Bonfa E. Silva CA, et al. Among authors: yuki efn. Nat Commun. 2022 Oct 3;13(1):5801. doi: 10.1038/s41467-022-33042-0. Nat Commun. 2022. PMID: 36192386 Free PMC article.
Strong response after fourth dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine.
Aikawa NE, Kupa LVK, Silva CA, Saad CGS, Pasoto SG, Yuki EFN, Fusco SRG, Shinjo SK, Andrade DCO, Sampaio-Barros PD, Pereira RMR, Chasin ACS, Shimabuco AY, Luppino-Assad AP, Leon EP, Lopes MH, Antonangelo L, Medeiros-Ribeiro AC, Bonfa E. Aikawa NE, et al. Among authors: yuki efn. Rheumatology (Oxford). 2022 Dec 23;62(1):480-485. doi: 10.1093/rheumatology/keac301. Rheumatology (Oxford). 2022. PMID: 35639644 Free PMC article.
Understanding the dynamics of hydroxychloroquine blood levels in lupus nephritis.
Pedrosa TN, Pasoto SG, Aikawa NE, Yuki EF, Borba EF, Filho JCF, Carricondo PC, Zanetti CB, Conde PG, Duarte NJ, Fontoura N, Romano P, Carvalho VM, Silva CA, Bonfa E. Pedrosa TN, et al. Lupus. 2020 May;29(6):560-568. doi: 10.1177/0961203320912832. Epub 2020 Mar 19. Lupus. 2020. PMID: 32192398 No abstract available.
Effect of an exercise bout before the booster dose of an inactivated SARS-CoV-2 vaccine on immunogenicity in immunocompromised patients.
Gualano B, Saad CGS, Sieczkowska SM, Lemes ÍR, da Silva RP, Pinto AJ, Mazzolani BC, Smaira FI, Gil S, Oliveira-Junior G, Aikawa NE, Medeiros-Ribeiro AC, Silva CA, Yuki EFN, Pasoto SG, Pereira RMR, Shinjo SK, Andrade DCO, Sampaio-Barros PD, Roschel H, Bonfa E. Gualano B, et al. Among authors: yuki efn. J Appl Physiol (1985). 2022 Mar 1;132(3):682-688. doi: 10.1152/japplphysiol.00015.2022. Epub 2022 Feb 10. J Appl Physiol (1985). 2022. PMID: 35142560 Free PMC article. Clinical Trial.
Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose.
Pereira RMR, Dagostin MA, Caparbo VF, Sales LP, Pasoto SG, Silva CA, Yuki EFN, Saad CGS, Medeiros-Ribeiro AC, Kupa LVK, Fusco SRG, Martins VAO, Martins CCMF, Barbas CV, Shinjo SK, Aikawa NE, Bonfa E. Pereira RMR, et al. Among authors: yuki efn. Clinics (Sao Paulo). 2022 Nov 29;78:100150. doi: 10.1016/j.clinsp.2022.100150. eCollection 2023. Clinics (Sao Paulo). 2022. PMID: 36529052 Free PMC article.
Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome.
Signorelli F, Balbi GGM, Aikawa NE, Silva CA, Kupa LVK, Medeiros-Ribeiro AC, Yuki EF, Pasoto SG, Saad CG, Borba EF, Seguro LPC, Pedrosa T, Oliveira VAA, Costa ALCS, Ribeiro CT, Santos REB, Andrade DCO, Bonfá E. Signorelli F, et al. Lupus. 2022 Jul;31(8):974-984. doi: 10.1177/09612033221102073. Epub 2022 May 20. Lupus. 2022. PMID: 35593174 Free PMC article.
27 results